Compare Incyte Corporation (INCY) vs Workday Inc (WDAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Workday Inc — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Workday Inc trades at $186.59 (market cap $45.26B). The key difference: Workday Inc is the larger of the two by market cap, and Workday Inc is more actively traded (2,342,190 versus 1,927,029). Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Workday Inc for 38 Days on average.
| INCY | WDAY | |
|---|---|---|
Market Cap | $22.85B | $45.26B |
Volume | 1,927,029 | 2,342,190 |
Sector | Health | Technology |
52-Week High | $129.93 | $245.67 |
52-Week Low | $83.80 | $112.55 |
Typical Hold Time | 33 Days | 38 Days |
Enterprise Value | $18.35B | $45.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% today, with a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 27.71% net income margin and 30.67% ROE. Recent news includes FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting growth beyond its key drug JAKAFI. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion, reflecting improved operational efficiency.
The outlook is positive with a consensus price target of $132.43, implying 17% upside, though near-term earnings pressure and JAKAFI's patent expiry after 2029 pose risks. Analyst sentiment is bullish (52% buy ratings), but technical indicators suggest caution with key support at $111. Execution on pipeline diversification remains critical for sustained growth.
Workday (WDAY) trades at $187.81, up 1.93% on the day, with a neutral technical signal and bullish moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $8.45B in 2025, and net income margin improved to 12.32%. Recent news highlights AI product launches and strategic partnerships, alongside a 2.5% headcount reduction aimed at realigning for growth.
WDAY presents a growth opportunity driven by AI integration and expanding market presence, but faces risks from competitive pressures and execution challenges. Analyst consensus is bullish with a $202.92 price target, though valuation multiples remain elevated. Investors should weigh strong fundamentals against potential volatility from market sentiment and operational adjustments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Workday Inc
Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →
